Why Mimosa?
The Mimosa tenuiflora tree is a symbol of ancient regenerative healing. In the 10th century, the Mayans were already utilizing its bark for its incredible capability to heal wounds. Today we have discovered that its roots also contains one of the highest levels of DMT from any botanical known to man. At MIMOSA, we aim to bring the healing power of entheogens such as the Mimosa tenuiflora tree back into service for greater good of humanity.
Origin Story
James Keim, Amanda Feilding, Bob Stanley, and other major figures in the psychedelic world shared a similar vision; they wanted to create an international company that would produce high-quality, natural entheogensDefinition: “becoming divine within” // chemical substance, typically of plant origin, that is ingested to produce a nonordinary state of consciousness for religious or spiritual purposes. at very affordable prices. Informed by ethical capitalism and grounded in morals and practices of the psychedelic community, Mimosa Therapeutics was formed as a Public Benefit Corporation.
Mission
To help people access the best, healthiest version of themselves through the careful and intentional use of entheogens.
Safe
Uniform.
Consistent.
Sacred.
Inclusive.
Organic.
Our Commitments as a Public Benefit Corporation
ETHICAL CAPITAL
Avoid capital that is not committed to ethical impact investment. Democratize access by providing much lower cost offerings (e.g., supplements, topicals, sacraments), and cost-effective tools to “grow your own” at individual, small group and larger group scales
RECIPROCITY
Engage reciprocity with traditional and emerging communities of practice, setting aside a % of profits for conservation, indigenous reciprocity, and for safety education and training. Participate in and learn from other experts in ethics and reciprocity, like Chacruna, RiverStyx
EQUITABLE ACCESS
Grow diversity within our team and in our partnerships
Financially support local community for inner city outreach/education through direct donations. Share high quality Offerings (e.g., therapeutics, sacrament, test kits) with low income communities (free)
SACRED OFFERINGS FOR THRIVING
Clean, pure, all-natural (not synthetic or genetically modified) Offerings. Whole plant/fungi and or extracted Offerings, NOT pharmaceutical compounds requiring capital-intensive pharmaceutical regulation
TRANSPARENCY & OPEN SHARING
Explore “impact” pledge patents to protect low capital access and grow potential for growth in access. Publish on open source / creative commons platform for all core science and discovery. Transparently defined Offerings (source ‘story, geography, ingredients, genetics, potency, purity, etc.) limit protective patenting to specific designs and/or formulations that offer unique advantages, but that do not limit broad engagement and access, e.g., by under-capitalized individuals and communities
A Team With Deep Roots
Leading Figures from the World of Psychedelics
Amanda Feilding
Co-founder, Director
The founder of the Beckley Foundation and one of the best-known and respected figures in the world of psychedelic research and drug policy.
James Keim
Co-founder, CEO
Previously served as CEO of OLP Therapeutics and other startups. He is also a psychedelic therapist, Fulbright Specialist, and co-author of the book, The Violence of Men.
Tyra Callaway
Vice President, Formulations
Brings significant experience from academic computational chemistry laboratories focused on drug design, protein function, and natural botanical preparations.
Bob Stanley
Chief Sacrament Officer, Senior Vice President
Bob Stanley is the Chief Garden Steward for Sacred Garden Community Church, was the co-founder of two previous life science informatics companies and was the founding chair of Decriminalize Nature, Oakland.
Antoni Gandia
Vice President For Bioreactor Production
He is the author of a book on mushrooms and of notable journal publications on mycelium. He has previously worked in the mycoprotien and mycoleather production industries.
Felix Blei
Vice President for Analytics
Is one of the world’s leading biochemists studying magic mushrooms and recently received the Paper of the Year award from Psychedelic Science Review.
John Turner
Senior Advisor
Before retiring, he served as a corporate attorney and business advisor in Silicon Valley for 17 years, most at Wilson Sonsini. John founded Trippingly.net , a leading source of reliable information on psychedelics.
James Fadiman
Chief Culture Officer
Author, researcher, and philosopher, he is one of the psychedelic world’s most popular figures and his books include The Psychedelic Explorer’s Guide.
Alan Rockefeller
Chief Mycologist
He is one of the world’s leading authorities on magic mushrooms with a special interest in understanding genetic variation among psilocybin varieties.
Jake Houbiers
Brand Strategist
Jake founded Dutch design agency, Ministry of MEDIA working for NGO’s, whilst teaching at the University of Utrecht. His expertise is in hard to reach audiences and design strategies that inspire meaningful & postive change.
Jonathan Keim
Creative Director
After launching Indonesia’s first vegan gelato brand and two world-renowned life coach training schools, Jonathan Keim started working as a Brand Strategist and Creative Director for impact-based businesses.
Amanda Feilding
Co-founder, Director
The founder of the Beckley Foundation and one of the best-known and respected figures in the world of psychedelic research and drug policy.
James Keim
Co-founder, CEO
Previously served as CEO of OLP Therapeutics and other startups. He is also a psychedelic therapist, Fulbright Specialist, and co-author of the book, The Violence of Men.
Tyra Callaway
Vice President, Formulations
Brings significant experience from academic computational chemistry laboratories focused on drug design, protein function, and natural botanical preparations.
Bob Stanley
Chief Sacrament Officer
Senior Vice President
Bob Stanley is the Chief Garden Steward for Sacred Garden Community Church, was the co-founder of two previous life science informatics companies and was the founding chair of Decriminalize Nature, Oakland.
Antoni Gandia
Vice President for Bioreactor Production
He is the author of a book on mushrooms and of notable journal publications on mycelium. He has previously worked in the mycoprotien and mycoleather production industries.
Felix Blei
Vice President for Analytics
Is one of the world’s leading biochemists studying magic mushrooms and recently received the Paper of the Year award from Psychedelic Science Review.
John Turner
Senior Advisor
Before retiring, he served as a corporate attorney and business advisor in Silicon Valley for 17 years, most at Wilson Sonsini. John founded Trippingly.net, a leading source of reliable information on psychedelics.
James Fadiman
Chief Culture Officer
Author, researcher, and philosopher, he is one of the psychedelic world’s most popular figures and his books include The Psychedelic Explorer’s Guide.
Alan Rockefeller
Chief Mycologist
He is one of the world’s leading authorities on magic mushrooms with a special interest in understanding genetic variation among psilocybin varieties.
Jonathan Keim
Creative Director
After launching Indonesia’s first vegan gelato brand and two world-renowned life coach training schools, Jonathan Keim started working as a Brand Strategist and Creative Director for impact-based businesses.
Jake Houbiers
Brand Strategist
Jake founded Dutch design agency, Ministry of MEDIA working for NGO’s, whilst teaching at the University of Utrecht. His expertise is in hard to reach audiences and design strategies that inspire meaningful & postive change.
Investors
Integrated is a venture fund partnering with value-aligned companies and entrepreneurs that are transforming the health and well-being of our communities around the globe.
They are on a mission to redefine healthcare through the advancement of medicines and the integration of transformative therapies.
MIMOSA is a team of world renowned experts utilizing cutting edge science, technology, testing and production methods to make consistent, measurable, medical-grade natural entheogens available to the market at affordable prices.